Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;96(51):e9427.
doi: 10.1097/MD.0000000000009427.

Impact of metformin on serum prostate-specific antigen levels: Data from the national health and nutrition examination survey 2007 to 2008

Jee Soo Park  1 , Kwang Suk Lee, Won Sik Ham, Byung Ha Chung, Kyo Chul Koo
Affiliations

Impact of metformin on serum prostate-specific antigen levels: Data from the national health and nutrition examination survey 2007 to 2008

Jee Soo Park et al. Medicine (Baltimore). 2017 Dec.

Abstract

Purpose: A possible association between metformin use and the development of prostate cancer (PCa) has been reported. However, there is limited information on the impact of long-term metformin use on serum prostate-specific antigen (PSA) levels. We investigated the association between exposure to metformin and PSA levels among diabetic patients who were not previously diagnosed with PCa.

Methods: The analytic sample consisted of 1363 US men aged above 40 in the National Health and Nutrition Examination Survey 2007 to 2008 cycle. Men who had previous diagnoses of PCa or prostatitis and men exposed to manipulations that might have affected PSA levels were excluded. Multivariate logistic regression analyses were used to evaluate the association between PSA levels and metformin use by adjusting for potential confounders.

Results: The mean PSA level of the overall population was 1.8 (standard deviation = 3.1) ng/mL. There were no differences in PSA levels according to the presence of diabetes (P = .517). Among patients with diabetes, metformin users exhibited significantly lower PSA levels compared with nonmetformin users (odds ratio = 0.790; 95% confidence interval 0.666-0.938; P = .007). However, no significant difference was found in PSA levels among men over duration of metformin use when levels were stratified by either 1 year or 5 years by Pearson's coefficient.

Conclusion: A negative association between serum PSA levels and metformin use was observed in patients with diabetes. Duration of metformin use did not influence PSA levels. Further studies are warranted to elucidate whether the reduction in PSA level with metformin truly reflects reduced risk of PCa development and progression.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Pearson correlation scatter plot of PSA levels and duration of metformin use. PSA = prostate-specific antigen.
See this image and copyright information in PMC

References

    1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–92. - PubMed
    1. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015;350:g7607. - PubMed
    1. Waters KM, Henderson BE, Stram DO, et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009;169:937–45. - PMC - PubMed
    1. Rastmanesh R, Hejazi J, Marotta F, et al. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. Clin Genitourin Cancer 2014;12:143–8. - PubMed
    1. Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004;53:1052–9. - PubMed